Algonomics
Lonza is a pioneer and world leader in the CDMO industry, dedicated to serving the healthcare industry by transforming therapeutic discoveries into viable therapies and manufacturing medicines of tomorrow. Founded in Switzerland in 1897, it has a global team of 18,500 colleagues across five continents, offering integrated solutions from early development to drug manufacturing, with expertise in biologics, small molecules, APIs, bioconjugates, mRNA, microbial, and cell and gene technologies. The company operates multiple locations worldwide, including facilities in Haifa, Israel; Houston, TX, USA; Istanbul, Turkey; Jakarta, Indonesia; Kingston, ON, Canada; Lexington, MA, USA; Manchester, United Kingdom; Mexico City, Mexico; Milan, Italy; Monteggio, Switzerland; Montreal, QC, Canada; Morristown, NJ, USA; Nansha, China; Oss, Netherlands; Porrino, Spain; Portsmouth, NH, USA; Puebla, Mexico; Rewari, India; Rio de Janeiro, Brazil; Rockland, ME, USA; Rockville, MD, USA; Sagamihara, Japan; Salisbury, MD, USA; San Jose, Costa Rica; Shanghai, China; Siena, Italy; Tuas, Singapore; Slough, UK; Stein, Switzerland; Stockholm, Sweden; Suzhou, China; Sydney, Australia; Tampa, FL, USA; Tokyo, Japan; Vacaville, CA, USA; Verviers, Belgium; Visp, Switzerland; Walkersville, MD, USA; Wayne, PA, USA; Wellington, New Zealand; and Budapest, Hungary. The company emphasizes sustainability, aiming to reduce environmental impact, conserve resources, and improve community well-being.
Industries
Nr. of Employees
Very Large (1000+)
Algonomics
Products
Closed automated cell therapy manufacturing platform
A closed and automated manufacturing platform for autologous cell therapy processing to support consistency and scalable production.
Large-scale mammalian bioreactor infrastructure
Commercial mammalian bioreactor infrastructure including multi-10,000 L reactors and extended network capacity to support late-stage and commercial biologics production.
In silico immunogenicity and aggregation prediction platforms
Computational platforms for immunogenicity risk profiling and aggregation/manufacturability prediction used to support early candidate selection and design.
Closed automated cell therapy manufacturing platform
A closed and automated manufacturing platform for autologous cell therapy processing to support consistency and scalable production.
Large-scale mammalian bioreactor infrastructure
Commercial mammalian bioreactor infrastructure including multi-10,000 L reactors and extended network capacity to support late-stage and commercial biologics production.
In silico immunogenicity and aggregation prediction platforms
Computational platforms for immunogenicity risk profiling and aggregation/manufacturability prediction used to support early candidate selection and design.
Services
End-to-end services from cell line development through process and analytical development to GMP drug substance and drug product manufacturing and tech transfer.
Computational developability and manufacturability assessments, antibody humanization and deimmunization, aggregation prediction, potency assays, in vitro immunosafety profiling and small-scale non-GMP protein expression for preclinical needs.
Formulation development, lyophilization cycle development, sterile process design and GMP fill–finish for injectable biologics and combination products.
API route scouting, continuous-flow and batch process development, scale-up, HPAPI containment, solid-form and formulation development, and clinical/commercial manufacturing for small molecules.
Process development and cGMP manufacture for autologous/allogeneic cell therapies and viral vectors, including closed automated solutions to support scalable production.
mRNA process development, drug substance manufacturing, LNP encapsulation and dedicated analytical testing for mRNA DS and LNP-formulated intermediates.
End-to-end services from cell line development through process and analytical development to GMP drug substance and drug product manufacturing and tech transfer.
Computational developability and manufacturability assessments, antibody humanization and deimmunization, aggregation prediction, potency assays, in vitro immunosafety profiling and small-scale non-GMP protein expression for preclinical needs.
Formulation development, lyophilization cycle development, sterile process design and GMP fill–finish for injectable biologics and combination products.
API route scouting, continuous-flow and batch process development, scale-up, HPAPI containment, solid-form and formulation development, and clinical/commercial manufacturing for small molecules.
Process development and cGMP manufacture for autologous/allogeneic cell therapies and viral vectors, including closed automated solutions to support scalable production.
mRNA process development, drug substance manufacturing, LNP encapsulation and dedicated analytical testing for mRNA DS and LNP-formulated intermediates.
Expertise Areas
- Biologics development and commercial manufacturing
- Cell and gene therapy process development and GMP manufacturing
- mRNA drug substance and LNP formulation development
- Small-molecule process development, scale-up and HPAPI containment
Key Technologies
- Mammalian cell culture and large-scale bioreactors (CHO platforms)
- Viral vector production for gene therapies
- Lipid nanoparticle encapsulation
- Spray drying and spray-dried dispersion technologies
News & Updates
Lonza’s stock
LONZA GROUP AG-REG, Last price CHF 566.60, Change +0.60%.
Today, we completed our acquisition of the Genentech biologics manufacturing site in Vacaville, California from Roche for USD 1.2 billion. The facility significantly extends our mammalian manufacturing footprint in the US.
We have just signed a long-term commercial supply agreement for CASGEVY® with Vertex Pharmaceuticals, to be manufactured at our facilities in Geleen (NL) and Portsmouth (US).
We inaugurated our newest facility - the Innovaform Accelerator, serving as a Center of Excellence for capsule-based manufacturing and delivery solutions.
We completed an expansion of our microbial manufacturing facility in Visp, Switzerland, enhancing scale flexibility.
We added clinical bottling and labeling capabilities at our Small Molecules site in Bend, Oregon, to speed up product delivery for clinical trials.
Lonza’s stock
LONZA GROUP AG-REG, Last price CHF 566.60, Change +0.60%.
Today, we completed our acquisition of the Genentech biologics manufacturing site in Vacaville, California from Roche for USD 1.2 billion. The facility significantly extends our mammalian manufacturing footprint in the US.
We have just signed a long-term commercial supply agreement for CASGEVY® with Vertex Pharmaceuticals, to be manufactured at our facilities in Geleen (NL) and Portsmouth (US).
We inaugurated our newest facility - the Innovaform Accelerator, serving as a Center of Excellence for capsule-based manufacturing and delivery solutions.
We completed an expansion of our microbial manufacturing facility in Visp, Switzerland, enhancing scale flexibility.
We added clinical bottling and labeling capabilities at our Small Molecules site in Bend, Oregon, to speed up product delivery for clinical trials.